ENARI: Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency
Study Details
Study Description
Brief Summary
Chronic kidney disease is widespread in the western world with bacterial infection and sepsis as common complication. It has been shown that innate immune defence, represented by dysfunction of neutrophil granulocytes, is impaired in chronic kidney disease. Another impact of chronic kidney disease on innate immunity is the chronic activation of neutrophils leading to high levels of inflammatory cytokines, thus contributing to protein oxidation. Oxidation of human serum albumin (HSA), the major plasma protein, occurs in chronic kidney disease and leads to further activation of neutrophils. Another important impact of HSA oxidation is the decrease of its binding capacity leading to impaired detoxification ability of albumin. This includes reduced clearance of endotoxin, a major component of the gram negative bacterial cell wall. Circulating endotoxin is recognized by complex formation with lipopolysaccharide binding protein (LBP) followed by binding to CD14 and toll-like receptor (TLR) 4. High systemic endotoxin levels occur in chronic kidney disease and may be the result of decreased clearance ability of HSA and increased gut permeability in combination with intestinal bacterial overgrowth. High systemic endotoxin is associated with worse outcome in several diseases and could be used as predictor for mortality in chronic kidney disease patients.
Endotoxemia in renal insufficiency leads to impaired neutrophil function and to increased albumin oxidation. Oxidized albumin is not able to bind endotoxin adequately any more, which leads to a further increase in oxidative stress and neutrophil dysfunction, resulting in a vicious cycle.
195 patients with renal dysfunction will be enrolled and divided into 5 groups. Additionally, samples of 25 age and sex-matched healthy controls will be collected.
This concept will change the understanding of several aspects of chronic kidney disease and will potentially help to stratify patients into different groups at risk according to their endotoxin status, and their immune and albumin dysfunction. The results of this study will have important implications into the development of novel therapeutic strategies
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Laboratory methods Endotoxin will be detected by an adapted limulus amoebocyte lysate assay. LBP and sCD14 will be determined by means of ELISA. HPLC will be used to determine nitrate, nitrite, albumin fractions, albumin binding capacity, iNOS expression and energy status of neutrophils. For investigation of oxidation driven by leukocyte derived myeloperoxidase, mass spectrometry analysis will be used. Carbonyl contents of proteins will be detected by ELISA. Neutrophil function and TLR2, 4 and 9 expression will be studied by flow cytometrical analysis. For cell culture tests, freshly isolated neutrophils or differentiated HL60 cells will be used and incubated with albumin and/or endotoxin. Stool samples will be used for 16srDNA sequencing of the gut microbiome.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| predialytic renal insufficiency Patents without renal replacement therapy |
|
| hemodialysis/hemofiltration patients patients undergoing regular hemodialysis/hemofiltration |
|
| peritoneal dialysis patients patients undergoing peritoneal dialysis |
|
| acute renal failure patients with acute renal failure |
|
| post renal transplantation patients after renal transplantation |
|
| healthy controls control group |
Outcome Measures
Primary Outcome Measures
- Endotoxin levels (EU/ml and qualitative positive/negative) [Day 0]
Percentage of patients with measurable endotoxin serum levels in each group.
Secondary Outcome Measures
- albumin oxidation (%), albumin binding capacity (ratio), neutrophil function (%), [Day 0]
We want to investigate the following in patients with different stages of chronic renal insufficiency. Albumin oxidation and function in correlation with the endotoxin status Endotoxin binding to albumin Neutrophil function, energy status and NO metabolism in correlation with the endotoxin status
- microbiome composition [Day 0]
In a subgroup of patients undergoing hemodialysis or peritoneal dialysis we will assess the composition of the gut micro biome in stool samples by 16s rDNA sequencing
Eligibility Criteria
Criteria
Inclusion Criteria:
Age between 18-80 years, informed consent Groups 1a, 1b, 2a, 2b, 3a, 3b Patients with chronic kidney disease as defined previously [65] either
1a) with an eGFR between 30 and 45 (KDIGO 3B)
-
- with an eGFR between 15 and 30 (KDIGO 4)
-
- undergoing hemodialysis for ESRD
2b) undergoing hemodiafiltration for ESRD
3a) undergoing peritoneal dialysis for ESRD without signs of infection
3b) undergoing peritoneal dialysis for ESRD with peritonitis ≥2 out of the 4 criteria (>100 leucocytes/50%neutrophils, cloudy peritoneal dialysate, typical clinical presentation with fever and abdominal pain, positive culture from the peritoneal dialysate)
Group 4 Patients with acute kidney injury (AKIN 3 [66] defined as an increase in serum creatinine to 300% (3-fold) from baseline or serum creatinine 4.0 mg/dl with an acute rise of at least 0.5mg/dl or urine output of < 0.3ml/kg/h 24h or anuria 12h) Initiation of acute renal replacement therapy
Group 5 Stable patients after kidney transplantation with either an eGFR > 45, between 30 and 45 or < 30
Group 6: Healthy controls
Exclusion Criteria:
- Malignancy, pregnancy,chronic inflammatory bowel disease, celiac disease, active alcohol abuse, any severe organ dysfunction unrelated to renal dysfunction Groups 1a, 1b, 2a, 2b, 3 Organ transplantation Clinical evidence of active infection (except for group 3b) Treatment with antibiotics within the last 2 weeks (except for group 3b)
Group 4 Preexisting ESRD
Group 5 Clinical evidence of active infection Treatment with antibiotics within the last 2 weeks
Group 6:
Any evidence of acute or chronic disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Internal Medicine | Graz | Austria | 8036 |
Sponsors and Collaborators
- Vanessa Stadlbauer-Koellner, MD
- Austrian Science Fund (FWF)
Investigators
- Principal Investigator: Vanessa Stadlbauer, MD, Medical Univeristy of Graz
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P23532